• NS7a, Apoptosis, and IFN-λ Suppression in SADS-CoV

  2026-08-19

  The reference study identifies NS7a as a major SADS-CoV apoptosis-inducing protein and maps an AIFM1–caspase-6–caspase-3 pathway that cleaves IRF3 and suppresses type III interferon production. Its cell and piglet experiments connect apoptosis with enhanced viral replication, while inhibitor treatment provides a mechanistic basis for testing caspase-directed antiviral strategies.

• Metronidazole Research Workflows

  2026-08-19

  Metronidazole supports two complementary research directions: anaerobic bacteria targeting and transporter-mediated drug interaction studies. This workflow-focused guide shows how to prepare the compound, design OAT3 and uptake assays, interpret microbiology endpoints, and troubleshoot reproducibility.

• Itraconazole as a Candida Biofilm Probe

  2026-08-18

  Itraconazole is a triazole antifungal agent with value beyond routine growth inhibition. This article shows how to use it as a mechanistic probe for Candida biofilm resistance, PP2A-regulated autophagy, CYP3A4 interaction studies, and assay design.

• Gemcitabine HCl: From Mechanism to MRI-Guided Translation

  2026-08-18

  A translational framework for using Gemcitabine HCl as a mechanistically defined cytotoxic benchmark, integrating DNA replication inhibition, apoptosis readouts, and longitudinal multianimal MRI in pancreatic cancer models.

• Bifendate (DDB): A Mechanism-to-Assay Guide

  2026-08-17

  Bifendate (DDB) is a multifunctional hepatoprotection agent whose lipid, autophagy, and drug-interaction phenotypes require more than a single endpoint. This guide converts its reported biology into a structured assay strategy, using a CYP induction study to clarify translational controls and experimental boundaries.

• PDHA1 Succinylation and Immune Escape in Cholangiocarcinoma

  2026-08-17

  This Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic–immune checkpoint in cholangiocarcinoma. The modification increases α-ketoglutarate accumulation, activates macrophage OXGR1–MAPK signaling, suppresses MHC-II antigen presentation, and reduces chemotherapy sensitivity; inhibiting succinylation with CPI-613 improved responses to gemcitabine and cisplatin in the reported models.

• JZL184 Workflow for MAGL Research

  2026-08-16

  JZL184 provides a direct way to test how monoacylglycerol lipase inhibition reshapes 2-AG tone, CB1 signaling, synaptic plasticity, and pain-related behavior. This workflow connects biochemical validation with neuronal, inflammatory, and affective assays while separating established evidence from translational hypotheses.

• SP2509: Lysine-specific demethylase 1 Antagonist

  2026-08-15

  SP2509 enables mechanism-led studies of LSD1 inhibition, H3K4 methylation, apoptosis induction in AML cells, and differentiation. This workflow-focused guide explains how to prepare the compound, connect target engagement with phenotype, and troubleshoot solubility, assay timing, and combination experiments.

• Azilsartan Medoxomil: AT1 Blockade in Hypertension

  2026-08-14

  The 2017 MiniReview by Hjermitslev and colleagues connects azilsartan’s persistent AT1-receptor binding with pharmacokinetic and clinical evidence in hypertension. Its main contribution is a translational synthesis showing why TAK 491 may provide durable blood-pressure reduction while also emphasizing that cardiovascular mortality benefits remain unproven.

• Bacitracin B1670: Practical Protocol and QC Guide

  2026-08-14

  Bacitracin (SKU B1670) is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers preparation, solvent selection, controls, and quality checks; the product is for scientific research only and not for diagnostic, clinical, or medical use.

• LY2603618: Chk1 Inhibitor Workflow Guide

  2026-08-13

  LY2603618 provides a time-controlled way to interrogate Chk1-dependent DNA damage tolerance, G2/M progression, and chemotherapy response in cancer models. This practical guide connects dose-response, cell-cycle, phospho-H2AX, and genome-integrity assays while clearly separating established product data from exploratory applications.

• Tofacitinib citrate: Reliable Assay Design

  2026-08-13

  A scenario-based guide to using Tofacitinib citrate (CP-690550 citrate), SKU A4135, in viability, proliferation, cytotoxicity, and inflammatory signaling assays. It connects formulation, concentration selection, solvent control, and endothelial interpretation to current JAK-inhibitor evidence.

• CX-4945: CK2 as a Cancer-State Vulnerability

  2026-08-12

  CX-4945 (Silmitasertib) is a selective CK2 inhibitor for dissecting oncogenic signaling, apoptosis, cell-cycle control, and therapy-resistant phenotypes. This article connects CK2 pharmacology with ECE-1c stability and shows how to design more informative cancer assays than viability testing alone.

• Nimbolide, RNF114, and PARP1 Trapping in BRCA Cancer

  2026-08-12

  The reference study identifies RNF114 as a PARylation-dependent E3 ubiquitin ligase that controls PARP1 removal from DNA lesions. Its inhibition by nimbolide produces broad repair-factor trapping, synthetic lethality in BRCA-mutated models, and activity against some forms of PARP inhibitor resistance.

• URB597 Workflows for FAAH and Pain Research

  2026-08-11

  Use URB597 (KDS-4103) to isolate FAAH-dependent endocannabinoid signaling from the broader pharmacology of cannabidiol. This practical guide connects selective enzyme inhibition with pain, neuroplasticity, and neuroinflammation assays while emphasizing preparation, sampling, and interpretation controls.

15280 records 1/1019 page Next 12345 下5页 Last page